Sector Update: Health Care Stocks Decline Late Afternoon

MT NewswiresDec 19 15:56 ET

Immix Biopharma Reports Initial Data From US Trial of NXC-201 CAR-T Therapy for AL Amyloidosis

MT NewswiresDec 19 11:38 ET

Immix Biopharma Announces Data From Four Patients in NEXICART-2 U.S. Trial

TipRanksDec 19 09:40 ET

Express News | Immix Biopharma Announces Initial Data From First Four Patients In NEXICART-2 US Study; Says All Four Patients Treated With NXC-201 Normalized Disease Markers Within 30 Days Of Dosing, Of Which, Two Are Already Classified As Complete

BenzingaDec 19 09:36 ET

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of Sterically-optimized CAR-T NXC-201 in Relapsed/refractory Light Chain (AL) Amyloidosis

GlobeNewswireDec 19 09:35 ET

Immix Biopharma Announces Publication of NXC-201 Clinical Results

TipRanksDec 16 09:55 ET